Ingersoll Rand Inc. (IR) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call presents a mixed outlook: strong PST performance and optimistic Life Sciences growth counterbalance concerns over ITS margin pressures and Middle East delays. While management's guidance remains unchanged, indicating stability, lack of detailed numerical guidance and flat Q2 expectations temper enthusiasm. Overall, the sentiment is neutral, with no significant catalysts for a strong stock price movement.
Key Financial Performance
Adjusted EPS $0.77 for the quarter, up 7% year-over-year. The increase was attributed to disciplined pricing, operational execution, and capital allocation.
Orders Up 5% year-over-year, resulting in a book-to-bill of 1.07x. However, there was a delay in orders of approximately $40 million due to the conflict in the Middle East, which is expected to be recovered later in the year.
Total Revenue Grew 8% year-over-year, finishing in line with expectations. Growth was driven by improved short-cycle activity and market conditions.
Adjusted EBITDA $469 million with an adjusted EBITDA margin of 25.4%. The margin was down year-over-year due to the flow-through on organic volume declines, the dilutive impact from tariffs, and strategic investments for commercial growth.
Free Cash Flow $163 million for the first quarter, finishing in line with expectations and normal working capital seasonality.
ITS Segment Revenue Grew 7% year-over-year. Adjusted EBITDA margin finished at 26.7%, down year-over-year due to organic volume declines, tariffs, and commercial investments.
PST Segment Revenue Organic revenue grew 4% year-over-year. Adjusted EBITDA was $122 million, up 15% year-over-year, with margins improving by 120 basis points due to strong operational execution.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Launch of new product technologies in power tools: Mid-single-digit organic growth driven by launches in new product technologies and short-cycle momentum.
Carbon capture technology: Ingersoll Rand selected to provide vacuum and blower applications for innovative carbon capture technology, applicable across transportation, power generation, and industrial engines.
Life Science bulk powder system: Integration of ITS product technologies into ILC Dover's end-to-end bulk powder system for pharmaceutical manufacturing.
China market performance: China outperformed the underlying market with positive organic order growth.
Middle East market impact: $40 million delay in orders due to Middle East conflict, with recovery expected throughout 2026.
Adjusted EBITDA: Finished at $469 million with a margin of 25.4%, reflecting strategic investments and tariff impacts.
Free cash flow: $163 million in Q1, aligning with expectations and normal seasonality.
Operational execution: Strong operational execution led to improved EBITDA margins in PST segment by 120 basis points.
M&A strategy: Robust acquisition pipeline with 10 transactions at LOI stage and focus on bolt-on acquisitions to strengthen core technologies.
Capital allocation: Prioritization of M&A, share repurchases, and quarterly dividends with leverage below 2x.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Delayed Orders Due to Middle East Conflict: Approximately $40 million in orders were delayed due to the conflict in the Middle East, impacting long-cycle projects. While some recovery has occurred, the situation introduces uncertainty in order fulfillment timelines.
Tariffs and Inflation: The company faces margin pressure from tariffs and inflation, which require ongoing mitigation efforts to minimize their impact on financial performance.
Organic Volume Declines: Year-over-year margin pressure was partly driven by declines in organic volume, which could affect profitability if not addressed.
Dependence on M&A for Growth: The company's growth strategy heavily relies on M&A, which introduces risks related to integration, valuation, and execution of acquisitions.
Timing of Large Projects: The timing of large projects has impacted order and revenue recognition, particularly in the PST segment, creating variability in financial performance.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth: Total company revenue is expected to grow between 2.5% and 4.5% for 2026, driven by organic growth of 1% at the midpoint, growth from M&A of approximately 2%, and a 0.5% FX tailwind.
Adjusted EBITDA: Expected to be in the range of $2.13 billion to $2.19 billion for 2026.
Adjusted EPS: Projected to fall within the range of $3.45 to $3.57, representing approximately 5% growth at the midpoint.
Free Cash Flow Conversion: Expected to be approximately 95% of adjusted net income for 2026.
Tax Rate: Anticipated adjusted tax rate of roughly 23% for 2026.
Capital Allocation: Continued prioritization of M&A, share repurchases, and quarterly dividends, supported by a strong balance sheet and liquidity of nearly $4 billion.
Order Recovery: Orders delayed due to Middle East conflict are expected to recover throughout 2026, with no anticipated impact on full-year revenue or adjusted EBITDA.
Tariffs and Inflation: No net impact expected on full-year guidance due to mitigation actions against tariffs and inflation.
M&A Contribution: 400 to 500 basis points of annualized inorganic revenue expected to be acquired in 2026, with additional deals anticipated to close in the coming months.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Quarterly Dividends: The company maintains its commitment to quarterly dividends as part of its capital allocation strategy.
Share Repurchases: The company prioritizes share repurchases as part of its capital allocation strategy, alongside M&A and quarterly dividends.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:What are the trends in short-cycle and long-cycle business activities?
A:In the U.S., short-cycle business activities are stabilizing and improving, with compressor activity stabilizing and encouraging order trends across several categories. The core tool business is growing organically at a mid-single-digit rate, and Precision Technology saw organic growth in short-cycle business. Long-cycle activities remain stable, with rising energy prices in Europe seen as a potential long-term tailwind. However, decision-making and finalizing POs are taking longer, particularly in the Middle East, where some projects have been delayed but are expected to recover by 2026.
Q:How does the guidance for the year reflect sequential improvement?
A:The full-year organic revenue guidance remains unchanged, expecting about 1% organic growth. Q1 was slightly negative but better than expected when excluding Middle East pushouts. Low single-digit organic growth is expected for Q2 to Q4, supported by solid backlog growth and ongoing momentum in short-cycle activity.
Q:What are the expectations for Q2 organic sales and EBITDA margin?
A:Organic sales for Q2 are expected to be flattish year-on-year, with EBITDA margins down 50 to 100 basis points year-on-year, primarily driven by ITS. Sequential margin improvement is expected from Q1 to Q2, with continued margin expansion in PST.
Q:What is the confidence level in ITS margins improving in the second half?
A:ITS margins are expected to improve in the second half due to better organic volume outlook, continued improvement in price-cost dynamics, full implementation of tariff-related pricing actions, and productivity initiatives, including restructuring benefits.
Q:What is the impact of tariffs on the business?
A:Tariff-related changes, inflationary movements, and mitigation measures are expected to net out relatively neutral for the full year. Tariff-related pricing actions have been implemented, and the impact is expected to moderate as the year progresses.
Q:What is the outlook for Life Sciences and its pipeline?
A:Life Sciences showed double-digit organic order growth in Q1, driven by reshoring investments in biopharma and API production in the U.S. Visibility is improving, and the pipeline looks strong, with collaborations with major biopharma companies to accelerate productivity and production.
Q:What is the trajectory for ITS EBITDA margins and the drivers behind it?
A:ITS EBITDA margins are expected to improve sequentially throughout the year, reaching approximately 30% in the back half. Drivers include better organic volumes, pricing actions, productivity initiatives, and direct material cost improvements.
Q:What is the impact of the Middle East conflict on orders and sales?
A:The Middle East conflict caused delays in long-cycle project orders but no cancellations. One-third of delayed orders were booked in April, and the impact is expected to be transitory. There was no meaningful impact on Q1 sales, and no significant impact is expected in Q2.
Q:What is the performance of the PST segment and its outlook?
A:PST showed 4% organic growth in Q1, driven by Life Sciences and short-cycle businesses. The segment is expected to sustain mid-single-digit growth, supported by strong order momentum and investments in commercial activities.
Q:What is the recurring revenue growth and its contribution to the business?
A:Recurring revenue exceeded $450 million last year, with a backlog of $1.1 billion in future revenue. The company is on track to achieve a $1 billion recurring revenue run rate by the end of 2027, driven by new solutions and customer loyalty.
Q:What is the outlook for the China market?
A:The company is outperforming the market in China through localized technologies and new solutions. While the overall market is not shrinking, it remains highly competitive. The company sees opportunities for growth in specific areas like medical devices.
Q:Review of Unclear Management Responses
A:Management avoided providing specific quantifications for certain impacts, such as the exact tariff-related costs in Q1 or the precise breakdown of ITS margin drivers. Additionally, while they mentioned strong order momentum and pipeline visibility in Life Sciences, they did not provide detailed numerical guidance for the segment's future growth.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Conditions improvement
East order
Fox pump
Fox srl
IRX differentiator
LOI stage
Relations Reynal
Relations statement
Reynal Chairman
Slide element
Today company
accumulator pulsation
acquisition core
activity approach
adjacency update
allocation Slide
allocation commitment
approach valuation
balance matter
capital seasonality
commitment repurchase
company funnel
complexity landscape
conflict Middle
consistency Conditions
dampener Fox
dampener pressure
deal month
delay conflict
delay order
deployment signing
differentiator pricing
dividend segment
line expectation
IR Transcript
Ingersoll Rand Inc. (IR) Presents at 16th Annual Wells Fargo Industrials & Materials Conference Transcript
Neutral6-10
Ingersoll Rand Inc. (IR) Q1 2026 Earnings Call Transcript
Unknown4-29
The earnings call presents a mixed outlook: strong PST performance and optimistic Life Sciences growth counterbalance concerns over ITS margin pressures and Middle East delays. While management's guidance remains unchanged, indicating stability, lack of detailed numerical guidance and flat Q2 expectations temper enthusiasm. Overall, the sentiment is neutral, with no significant catalysts for a strong stock price movement.
Ingersoll Rand Inc. (IR) Presents at Citi's Global Industrial Tech & Mobility Conference 2026 Transcript
Neutral2-19
Ingersoll Rand Inc. (IR) Presents at Barclays 43rd Annual Industrial Select Conference Transcript
Neutral2-18
IR Slides
IR Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
